

Technology appraisal (TA) Titles are hyperlinks to full guidance	Date of TA Release (N.B. if exact date is not specified in NICE documentation, the last day of the month published will be employed)	Adherence of local formulary to NICE				
		Yes (mark 'x' if applicable)	N/A (mark 'x' if applicable)	Date of local decision (DD/MM/YY)	Time to implement (days)	Notes (e.g. Additional stipulations, rationale, method of making available)
2017-18						
Cabozantinib for treating medullary thyroid cancer [TA516]	28/03/2018	X		17/04/2018	20	
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen [TA515]	28/03/2018	X		28/03/2018	0	Not recommended for use by NICE
Regorafenib for previously treated advanced hepatocellular carcinoma [TA514]	21/03/2018	X		21/03/2018	0	Not recommended for use by NICE
Obinutuzumab for untreated advanced follicular lymphoma [TA513]	21/03/2018	X		17/04/2018	27	
Tivozanib for treating advanced renal cell carcinoma [TA512]	21/03/2018	X		17/04/2018	27	
Brodalumab for treating moderate to severe plaque psoriasis [TA511]	21/03/2018	X		19/04/2018	29	
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma [TA510]	14/03/2018	X		17/04/2018	34	
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer [TA509]	07/03/2018	X		17/04/2018	41	
Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee [TA508]	07/03/2018		X	07/03/2018	0	No providers in SE London commissioned for this service
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C [TA507]	21/02/2018	X		17/04/2018	55	
Lesinurad for treating chronic hyperuricaemia in people with gout [TA506]	07/02/2018	X		07/02/2018	0	Not recommended for use by NICE
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [TA505]	07/02/2018	X		17/04/2018	69	
Pirfenidone for treating idiopathic pulmonary fibrosis [TA504]	06/02/2018	X		17/04/2018	70	
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer [TA503]	31/01/2018	X		31/01/2018	0	Not recommended for use by NICE
Ibrutinib for treating relapsed or refractory mantle cell lymphoma [TA502]	31/01/2018	X		17/04/2018	76	
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer [TA501]	31/01/2018	X		31/01/2018	0	Not recommended for use by NICE
Ceritinib for untreated ALK-positive non-small-cell lung cancer [TA500]	24/01/2018	X		17/04/2018	83	
Glecaprevir–pibrentasvir for treating chronic hepatitis C [TA499]	24/01/2018	X		17/04/2018	83	

Lenvatinib with everolimus for previously treated advanced renal cell carcinoma [TA498]	24/01/2018	X		17/04/2018	83	
Golimumab for treating non-radiographic axial spondyloarthritis [TA497]	10/01/2018	X		18/01/2018	8	
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [TA496]	20/12/2017	X		23/01/2018	34	
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [TA495]	20/12/2017	X		23/01/2018	34	
Naltrexone–bupropion for managing overweight and obesity [TA494]	12/12/2017	X		12/12/2017	0	Not recommended for use by NICE
Cladribine tablets for treating relapsing–remitting multiple sclerosis [TA493]	06/12/2017	X		23/01/2018	48	
Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable [TA492]	06/12/2017	X		23/01/2018	48	
Ibrutinib for treating Waldenstrom's macroglobulinaemia [TA491]	22/11/2017	X		23/01/2018	62	
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy [TA490]	22/11/2017	X		23/01/2018	62	
Vismodegib for treating basal cell carcinoma [TA489]	22/11/2017	X		22/11/2017	0	Not recommended for use by NICE
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours [TA488]	15/11/2017	X		23/01/2018	69	
Venetoclax for treating chronic lymphocytic leukaemia [TA487]	01/11/2017	X		23/01/2018	83	
Aflibercept for treating choroidal neovascularisation [TA486]	01/11/2017	X		16/11/2017	15	
Sarilumab for moderate to severe rheumatoid arthritis [TA485]	01/11/2017	X		16/11/2017	15	
Nivolumab for previously treated non-squamous non-small-cell lung cancer [TA484]	01/11/2017	X		23/01/2018	83	
Nivolumab for previously treated squamous non-small-cell lung cancer [TA483]	01/11/2017	X		23/01/2018	83	
Immunosuppressive therapy for kidney transplant in children and young people [TA482]	11/10/2017	X		17/10/2017	6	
Immunosuppressive therapy for kidney transplant in adults [TA481]	11/10/2017	X		17/10/2017	6	
Tofacitinib for moderate to severe rheumatoid arthritis [TA480]	11/10/2017	X		19/10/2017	8	
Reslizumab for treating severe eosinophilic asthma [TA479]	04/10/2017	X		17/10/2017	13	
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma [TA478]	04/10/2017	X		17/10/2017	13	

Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee	04/10/2017		X	04/10/2017	0	No providers in SE London commissioned for this service
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer [TA476]	06/09/2017	X		17/10/2017	41	
Dimethyl fumarate for treating moderate to severe plaque psoriasis [TA475]	06/09/2017	X		21/09/2017	15	
Sorafenib for treating advanced hepatocellular carcinoma [TA474]	06/09/2017	X		17/10/2017	41	
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck [TA473]	31/08/2017	X		17/10/2017	47	
Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab [TA472]	30/08/2017	X		17/10/2017	48	
Eluxadoline for treating irritable bowel syndrome with diarrhoea [TA471]	30/08/2017	X		21/09/2017	22	
Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) [TA470]	23/08/2017		X	23/08/2017	0	
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) [TA469]	23/08/2017		X	23/08/2017	0	
Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) [TA468]	23/08/2017		X	23/08/2017	0	
Holoclar for treating limbal stem cell deficiency after eye burns [TA467]	16/08/2017	X		13/11/2017	89	
Baricitinib for moderate to severe rheumatoid arthritis [TA466]	09/08/2017	X		21/09/2017	43	
Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma [TA465]	09/08/2017	X		17/10/2017	69	
Bisphosphonates for treating osteoporosis [TA464]	09/08/2017	X		21/09/2017	43	
Cabozantinib for previously treated advanced renal cell carcinoma [TA463]	09/08/2017	X		17/10/2017	69	
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma [TA462]	26/07/2017	X		17/10/2017	83	
Roflumilast for treating chronic obstructive pulmonary disease [TA461]	26/07/2017	X		17/08/2017	22	
Adalimumab and dexamethasone for treating non-infectious uveitis [TA460]	26/07/2017	X		17/10/2017	83	
Collagenase clostridium histolyticum for treating Dupuytren's contracture [TA459]	26/07/2017	X		17/08/2017	22	
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane [TA458]	19/07/2017	X		17/10/2017	90	
Carfilzomib for previously treated multiple myeloma [TA457]	19/07/2017	X		17/10/2017	90	

Ustekinumab for moderately to severely active Crohn's disease after previous treatment [TA456]	12/07/2017	X		17/08/2017	36	
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people [TA455]	12/07/2017	X		17/08/2017	36	
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) [TA454]	05/07/2017		X	05/07/2017	0	
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) [TA453]	05/07/2017		X	05/07/2017	0	
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) [TA452]	05/07/2017		X	05/07/2017	0	
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma [TA446]	28/06/2017	X		11/07/2017	13	
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [TA447]	28/06/2017	X		11/07/2017	13	
Etelcalcetide for treating secondary hyperparathyroidism [TA448]	28/06/2017	X		11/07/2017	13	
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease [TA449]	28/06/2017	X		11/07/2017	13	
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia [TA450]	28/06/2017	X		11/07/2017	13	
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia [TA451]	28/06/2017	X		11/07/2017	13	
Afinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) [TA444]	24/05/2017		X	24/05/2017	0	
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs [TA445]	24/05/2017	X		15/06/2017	22	
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine [TA440]	26/04/2017	X		26/04/2017	0	Not recommended for use by NICE
Daclizumab for treating relapsing–remitting multiple sclerosis [TA441]	26/04/2017	X		11/07/2017	76	
Ixekizumab for treating moderate to severe plaque psoriasis [TA442]	26/04/2017	X		18/05/2017	22	
Obeticholic acid for treating primary biliary cholangitis [TA443]	26/04/2017	X		11/07/2017	76	
		% "Yes"	% "N/A"	–	Average implement time (days)	
Adherence statistics for 2017-18		88.0%	12.0%		34	

1